Patient capital

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024
Aphelion, Sector, FDA, ISC, EQT, Dysphagia, Pneumonia, Stroke, Entrepreneurship, Risk, Conference, Health Economics, Saliva, Patient, Brain, Patient capital, Economics, Mortality, Research, Pharmaceutical industry

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.

Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management

Retrieved on: 
Monday, March 4, 2024
Aphelion, Sector, FDA, ISC, EQT, Dysphagia, Pneumonia, Stroke, Entrepreneurship, Risk, Conference, Health Economics, Saliva, Patient, Brain, Patient capital, Economics, Mortality, Research, Pharmaceutical industry

The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.

Key Points: 
  • The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
  • Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
  • Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
  • Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

Retrieved on: 
Wednesday, July 12, 2023
Biotechnology, Health, Science, Research, Optical, University, Therapy, AMD, Sofinnova, Eye, Paratriathlon, Cell, Doctor of Philosophy, ARCH Venture Partners, Regenerative medicine, Moorfields Eye Hospital, Patient, University of Washington Department of Bioengineering, Vision Institute, Capital, FDA, Patient capital, Pharmaceutical industry, Management, Ophthalmology, MD

F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.

Key Points: 
  • F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
  • Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
  • “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue.
  • Vanessa King, PhD, Tenpoint’s founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor.

OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

Retrieved on: 
Monday, May 15, 2023
Workforce, Public sector banks in India, Therapy, Senior, Anticalin, G protein-coupled receptor, GV, Biotechnology, BPC, ARC, Business, Independent director, NED, Orphan drug, Weapon Shop de Omasse, Third Rock Ventures, R, Rare, Rest, Patient capital, Chair, Pharmaceutical industry, Fine chemical, Management, Genzyme, Geraghty, Sanofi

It will be used to support OMass as it continues to progress its pipeline of small molecule therapeutics for rare diseases and immunological conditions targeting solute carriers, complex-bound proteins and GPCRs.

Key Points: 
  • It will be used to support OMass as it continues to progress its pipeline of small molecule therapeutics for rare diseases and immunological conditions targeting solute carriers, complex-bound proteins and GPCRs.
  • Catherine Lewis La Torre, CEO, British Patient Capital said: “The UK continues to demonstrate its strength in life sciences with university spinouts like OMass leading the way.
  • Scaling next-generation technology businesses, like OMass, by providing long-term capital for investment is why we established Future Fund: Breakthrough in 2021.
  • Jim Geraghty, Chairman of OMass Therapeutics said: “OMass is on a growth trajectory, and I am thrilled to join the board at this exciting time in its journey.

Quantum Motion Raises £42 Million Investment Round Led By Bosch Ventures

Retrieved on: 
Tuesday, February 21, 2023
CMOS, Porsche, Porsche SE, Quantum theory, IP Group, Computer, SE, Electronic structure, Professor, Oxford Sciences Enterprises, Silicon, University of Oxford, Growth, UCL, Chair, Patient capital, Motion, Octopus Group, Collection, Microscope, Cryptocurrency, Quantum, EU

LONDON, Feb. 21, 2023 /PRNewswire/ -- Quantum Motion, a UK-based quantum computing scale-up founded by Professor John Morton, UCL, and Professor Simon Benjamin, Oxford University, has raised over £42 million in equity funding from some of the world's leading quantum and technology investors. The oversubscribed round is led by Bosch Ventures (RBVC) and joined by Porsche Automobil Holding SE (Porsche SE) and British Patient Capital. All existing investors from earlier rounds (Oxford Science Enterprises, Inkef, Parkwalk Advisors, Octopus Ventures, IP Group and NSSIF) are again participating. This is one of the most significant raises in UK quantum computing and allows Quantum Motion to accelerate its development of silicon quantum processors by developing deeper ties with its manufacturing partners and trebling the size of its central London headquarters. 

Key Points: 
  • The oversubscribed round is led by Bosch Ventures (RBVC) and joined by Porsche Automobil Holding SE (Porsche SE) and British Patient Capital .
  • This is one of the most significant raises in UK quantum computing and allows Quantum Motion to accelerate its development of silicon quantum processors by developing deeper ties with its manufacturing partners and trebling the size of its central London headquarters.
  • Quantum Motion has demonstrated that it can take quantum theory out of a lab into the real world to create a scalable path to a quantum future.
  • Neil Cameron, Investor Director at Parkwalk, said, "Parkwalk, a founder investor in the UK quantum industry, is delighted to follow its investment in Quantum Motion.

Quantum Motion Raises £42 Million Investment Round Led By Bosch Ventures

Retrieved on: 
Tuesday, February 21, 2023
CMOS, Porsche, Porsche SE, Quantum theory, IP Group, Computer, SE, Electronic structure, Professor, Oxford Sciences Enterprises, Silicon, University of Oxford, Growth, UCL, Chair, Patient capital, Motion, Octopus Group, Collection, Microscope, Cryptocurrency, Quantum, EU

LONDON, Feb. 21, 2023 /PRNewswire/ -- Quantum Motion, a UK-based quantum computing scale-up founded by Professor John Morton, UCL, and Professor Simon Benjamin, Oxford University, has raised over £42 million in equity funding from some of the world's leading quantum and technology investors. The oversubscribed round is led by Bosch Ventures (RBVC) and joined by Porsche Automobil Holding SE (Porsche SE) and British Patient Capital. All existing investors from earlier rounds (Oxford Science Enterprises, Inkef, Parkwalk Advisors, Octopus Ventures, IP Group and NSSIF) are again participating. This is one of the most significant raises in UK quantum computing and allows Quantum Motion to accelerate its development of silicon quantum processors by developing deeper ties with its manufacturing partners and trebling the size of its central London headquarters. 

Key Points: 
  • The oversubscribed round is led by Bosch Ventures (RBVC) and joined by Porsche Automobil Holding SE (Porsche SE) and British Patient Capital .
  • This is one of the most significant raises in UK quantum computing and allows Quantum Motion to accelerate its development of silicon quantum processors by developing deeper ties with its manufacturing partners and trebling the size of its central London headquarters.
  • Quantum Motion has demonstrated that it can take quantum theory out of a lab into the real world to create a scalable path to a quantum future.
  • Neil Cameron, Investor Director at Parkwalk, said, "Parkwalk, a founder investor in the UK quantum industry, is delighted to follow its investment in Quantum Motion.

Microbiotica Announces Transition of Leadership

Retrieved on: 
Tuesday, November 29, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ICON, Pleasure, Cros, Patient capital, Arrakis, IBD, Faculty, IP Group, Biomarker, Wellcome Sanger Institute, Medical school, Tencent, Dean (education), Ulcerative colitis, Therapy, Medicine, Biology, Imperial College London, Management, Pharmaceutical industry, Antibiotics

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, announces a change of leadership as Mike Romanos hands over the Microbiotica CEO role to current COO, Tim Sharpington.

Key Points: 
  • Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, announces a change of leadership as Mike Romanos hands over the Microbiotica CEO role to current COO, Tim Sharpington.
  • Microbiotica is a leading player in microbiome-based therapeutics and biomarkers.
  • As the founding CEO, Mike has led Microbiotica over six years to become one of the leaders in the microbiome sector.
  • Through his strategic vision, scientific expertise and leadership, he has built Microbiotica into one of the leading microbiome companies.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines

Retrieved on: 
Wednesday, October 19, 2022
Merck, Disease, Future, Machine learning, Johnson & Johnson, Technology, Publication, Company, Drug discovery, Merck Group, Protein, Genetics, Genome, Gene, Patient capital, Pharmaceutical industry, Antibiotics, Pfizer

The funds will be used to advance the Company's autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

Key Points: 
  • The funds will be used to advance the Company's autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.
  • Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the dark region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes.
  • Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.
  • Unlocking the value of the largely unexplored territory of the genome can lead to the identification of high-value drug targets.

Precision Immersion Cooling Specialist, Iceotope Technologies, Secures £30m Funding from Global Syndicate Led by Impact Investor ABC Impact

Retrieved on: 
Wednesday, July 6, 2022
Agriculture, United Nations, Adoption, Climate, Sustainable development, Industry, Market, ITE, Environment, Saudi Research and Marketing Group, Year, City, Component, IOT, Immersion, Efficiency, Civilization, Achievement, SP Group, HPC, Food, CAGR, STL, Syndicate, Solution, Research, Education, First Nations in Ontario, CEO, Carbon, Chassis, Climate change, Patient capital, ABC, FTSE, FTSE 250, Technology, Health, Water, Region, Faith and Beauty Society, Temasek, Goal, Maintenance, Mapletree Investments, Sembcorp, Renewable energy, Security (finance), Heating, ventilation, and air conditioning, Printed circuit board

This alliance will further drive the rapid deployment of Iceotope's technology globally through its holistic suite of data centre solutions.

Key Points: 
  • This alliance will further drive the rapid deployment of Iceotope's technology globally through its holistic suite of data centre solutions.
  • Tan Shao Ming, Chief Investment Officer at ABC Impact said: "Climate and water solutions form a key investment theme for us.
  • Iceotope's precision cooling solutions enable data centres to transit to a more sustainable infrastructure with a reduced environmental and real estate footprint.
  • By increasing efficiency in their use of energy and water, data centres can contribute to global efforts to reduce carbonemissions.

Precision Immersion Cooling Specialist, Iceotope Technologies, Secures £30m Funding from Global Syndicate Led by Impact Investor ABC Impact

Retrieved on: 
Wednesday, July 6, 2022
Agriculture, United Nations, Adoption, Climate, Sustainable development, Industry, Market, ITE, Environment, Saudi Research and Marketing Group, Year, City, Component, IOT, Immersion, Efficiency, Civilization, Achievement, SP Group, HPC, Food, CAGR, STL, Syndicate, Solution, Research, Education, First Nations in Ontario, CEO, Carbon, Chassis, Climate change, Patient capital, ABC, FTSE, FTSE 250, Technology, Health, Water, Region, Faith and Beauty Society, Temasek, Goal, Maintenance, Mapletree Investments, Sembcorp, Renewable energy, Security (finance), Heating, ventilation, and air conditioning, Printed circuit board

This alliance will further drive the rapid deployment of Iceotope's technology globally through its holistic suite of data centre solutions.

Key Points: 
  • This alliance will further drive the rapid deployment of Iceotope's technology globally through its holistic suite of data centre solutions.
  • Tan Shao Ming, Chief Investment Officer at ABC Impact said: "Climate and water solutions form a key investment theme for us.
  • Iceotope's precision cooling solutions enable data centres to transit to a more sustainable infrastructure with a reduced environmental and real estate footprint.
  • By increasing efficiency in their use of energy and water, data centres can contribute to global efforts to reduce carbonemissions.